Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) Stock Competitors & Peer Comparison
See IMDX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for IMDX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| IMDX | $4.02 | -4.29% | 129.8M | -2.70 | -$1.49 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.72% |
| TMO | $613.62 | +0.62% | 228.1B | 26.50 | $23.16 | +0.29% |
| DHR | $203.25 | +1.55% | 142.9B | 25.48 | $7.98 | +0.72% |
| NTRA | $341.79 | +3.91% | 48.9B | -258.93 | -$1.32 | N/A |
| IQV | $265.67 | +1.49% | 43.7B | 21.91 | $12.13 | N/A |
| A | $146.80 | -0.09% | 41.5B | 25.27 | $5.81 | +0.69% |
| IDXX | $509.56 | +0.96% | 40.2B | 35.83 | $14.22 | N/A |
| ILMN | $208.21 | +0.85% | 31.5B | 41.39 | $5.03 | N/A |
| WAT | $410.01 | +0.41% | 30.7B | 29.97 | $13.68 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
IMDX vs DHR-PB Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, IMDX's ROE is +2.72%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, IMDX is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
IMDX vs TMO Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, TMO has a market cap of 228.1B. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while TMO trades at $613.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas TMO's P/E ratio is 26.50. In terms of profitability, IMDX's ROE is +2.72%, compared to TMO's ROE of +0.13%. Regarding short-term risk, IMDX is more volatile compared to TMO. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
IMDX vs DHR Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, DHR has a market cap of 142.9B. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while DHR trades at $203.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas DHR's P/E ratio is 25.48. In terms of profitability, IMDX's ROE is +2.72%, compared to DHR's ROE of +0.08%. Regarding short-term risk, IMDX is more volatile compared to DHR. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
IMDX vs NTRA Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, NTRA has a market cap of 48.9B. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while NTRA trades at $341.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas NTRA's P/E ratio is -258.93. In terms of profitability, IMDX's ROE is +2.72%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, IMDX is more volatile compared to NTRA. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check NTRA's competition here
IQVIA Holdings Inc. (NYSE: IQV)
IMDX vs IQV Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, IQV has a market cap of 43.7B. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while IQV trades at $265.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas IQV's P/E ratio is 21.91. In terms of profitability, IMDX's ROE is +2.72%, compared to IQV's ROE of +0.22%. Regarding short-term risk, IMDX is more volatile compared to IQV. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check IQV's competition here
Agilent Technologies, Inc. (NYSE: A)
IMDX vs A Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, A has a market cap of 41.5B. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while A trades at $146.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas A's P/E ratio is 25.27. In terms of profitability, IMDX's ROE is +2.72%, compared to A's ROE of +0.20%. Regarding short-term risk, IMDX is more volatile compared to A. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check A's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
IMDX vs IDXX Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, IDXX has a market cap of 40.2B. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while IDXX trades at $509.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas IDXX's P/E ratio is 35.83. In terms of profitability, IMDX's ROE is +2.72%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, IMDX is more volatile compared to IDXX. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check IDXX's competition here
Illumina, Inc. (NASDAQ: ILMN)
IMDX vs ILMN Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, ILMN has a market cap of 31.5B. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while ILMN trades at $208.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas ILMN's P/E ratio is 41.39. In terms of profitability, IMDX's ROE is +2.72%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, IMDX is more volatile compared to ILMN. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check ILMN's competition here
Waters Corporation (NYSE: WAT)
IMDX vs WAT Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, WAT has a market cap of 30.7B. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while WAT trades at $410.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas WAT's P/E ratio is 29.97. In terms of profitability, IMDX's ROE is +2.72%, compared to WAT's ROE of +0.02%. Regarding short-term risk, IMDX is more volatile compared to WAT. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check WAT's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
IMDX vs DGX Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, DGX has a market cap of 26.2B. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while DGX trades at $237.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas DGX's P/E ratio is 23.45. In terms of profitability, IMDX's ROE is +2.72%, compared to DGX's ROE of +0.14%. Regarding short-term risk, IMDX is more volatile compared to DGX. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check DGX's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
IMDX vs MTD Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, MTD has a market cap of 26B. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while MTD trades at $1,285.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas MTD's P/E ratio is 29.54. In terms of profitability, IMDX's ROE is +2.72%, compared to MTD's ROE of -12.00%. Regarding short-term risk, IMDX is more volatile compared to MTD. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check MTD's competition here
Labcorp Holdings Inc. (NYSE: LH)
IMDX vs LH Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, LH has a market cap of 25.9B. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while LH trades at $315.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas LH's P/E ratio is 18.72. In terms of profitability, IMDX's ROE is +2.72%, compared to LH's ROE of +0.12%. Regarding short-term risk, IMDX is more volatile compared to LH. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check LH's competition here
Guardant Health, Inc. (NASDAQ: GH)
IMDX vs GH Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, GH has a market cap of 22.5B. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while GH trades at $167.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas GH's P/E ratio is -48.09. In terms of profitability, IMDX's ROE is +2.72%, compared to GH's ROE of +2.11%. Regarding short-term risk, IMDX is less volatile compared to GH. This indicates lower risk in terms of short-term price fluctuations for IMDX.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
IMDX vs EXAS Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas EXAS's P/E ratio is -95.37. In terms of profitability, IMDX's ROE is +2.72%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, IMDX is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check EXAS's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
IMDX vs ILMNV Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas ILMNV's P/E ratio is N/A. In terms of profitability, IMDX's ROE is +2.72%, compared to ILMNV's ROE of N/A. Regarding short-term risk, IMDX is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check ILMNV's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
IMDX vs MEDP Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, MEDP has a market cap of 16.6B. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while MEDP trades at $595.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas MEDP's P/E ratio is 34.90. In terms of profitability, IMDX's ROE is +2.72%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, IMDX is more volatile compared to MEDP. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check MEDP's competition here
PerkinElmer, Inc. (NYSE: PKI)
IMDX vs PKI Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas PKI's P/E ratio is 41.45. In terms of profitability, IMDX's ROE is +2.72%, compared to PKI's ROE of +0.03%. Regarding short-term risk, IMDX is more volatile compared to PKI. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check PKI's competition here
Revvity, Inc. (NYSE: RVTY)
IMDX vs RVTY Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, RVTY has a market cap of 14.3B. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while RVTY trades at $128.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas RVTY's P/E ratio is 24.02. In terms of profitability, IMDX's ROE is +2.72%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, IMDX is more volatile compared to RVTY. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check RVTY's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
IMDX vs CRL Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, CRL has a market cap of 13.1B. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while CRL trades at $273.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas CRL's P/E ratio is 27.58. In terms of profitability, IMDX's ROE is +2.72%, compared to CRL's ROE of -0.08%. Regarding short-term risk, IMDX is more volatile compared to CRL. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check CRL's competition here
ICON Public Limited Company (NASDAQ: ICLR)
IMDX vs ICLR Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, ICLR has a market cap of 12.9B. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while ICLR trades at $168.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas ICLR's P/E ratio is 13.78. In terms of profitability, IMDX's ROE is +2.72%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, IMDX is more volatile compared to ICLR. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check ICLR's competition here
Qiagen N.V. (NYSE: QGEN)
IMDX vs QGEN Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, QGEN has a market cap of 8.6B. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while QGEN trades at $41.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas QGEN's P/E ratio is 17.30. In terms of profitability, IMDX's ROE is +2.72%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, IMDX is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check QGEN's competition here
RadNet, Inc. (NASDAQ: RDNT)
IMDX vs RDNT Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, RDNT has a market cap of 5.9B. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while RDNT trades at $75.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas RDNT's P/E ratio is 164.11. In terms of profitability, IMDX's ROE is +2.72%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, IMDX is more volatile compared to RDNT. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check RDNT's competition here
Sotera Health Company (NASDAQ: SHC)
IMDX vs SHC Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, SHC has a market cap of 5.3B. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while SHC trades at $18.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas SHC's P/E ratio is 19.29. In terms of profitability, IMDX's ROE is +2.72%, compared to SHC's ROE of +0.27%. Regarding short-term risk, IMDX is more volatile compared to SHC. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check SHC's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
IMDX vs BLLN Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, BLLN has a market cap of 4.6B. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while BLLN trades at $100.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas BLLN's P/E ratio is 144.03. In terms of profitability, IMDX's ROE is +2.72%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, IMDX is more volatile compared to BLLN. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check BLLN's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
IMDX vs SYNH Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas SYNH's P/E ratio is 61.40. In terms of profitability, IMDX's ROE is +2.72%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, IMDX is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check SYNH's competition here
Veracyte, Inc. (NASDAQ: VCYT)
IMDX vs VCYT Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, VCYT has a market cap of 3.3B. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while VCYT trades at $41.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas VCYT's P/E ratio is 20.61. In terms of profitability, IMDX's ROE is +2.72%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, IMDX is more volatile compared to VCYT. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check VCYT's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
IMDX vs OLK Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas OLK's P/E ratio is -96.59. In terms of profitability, IMDX's ROE is +2.72%, compared to OLK's ROE of -0.07%. Regarding short-term risk, IMDX is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check OLK's competition here
GRAIL Inc. (NASDAQ: GRAL)
IMDX vs GRAL Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, GRAL has a market cap of 3.2B. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while GRAL trades at $75.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas GRAL's P/E ratio is -7.75. In terms of profitability, IMDX's ROE is +2.72%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, IMDX is more volatile compared to GRAL. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check GRAL's competition here
CareDx, Inc (NASDAQ: CDNA)
IMDX vs CDNA Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, CDNA has a market cap of 2.7B. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while CDNA trades at $52.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas CDNA's P/E ratio is 62.35. In terms of profitability, IMDX's ROE is +2.72%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, IMDX is more volatile compared to CDNA. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check CDNA's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
IMDX vs WGS Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, WGS has a market cap of 2.7B. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while WGS trades at $89.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas WGS's P/E ratio is 249.28. In terms of profitability, IMDX's ROE is +2.72%, compared to WGS's ROE of -0.39%. Regarding short-term risk, IMDX is more volatile compared to WGS. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check WGS's competition here
Personalis, Inc. (NASDAQ: PSNL)
IMDX vs PSNL Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while PSNL trades at $16.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas PSNL's P/E ratio is -14.94. In terms of profitability, IMDX's ROE is +2.72%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, IMDX is more volatile compared to PSNL. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
IMDX vs OPK Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, OPK has a market cap of 1.2B. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while OPK trades at $1.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas OPK's P/E ratio is -5.78. In terms of profitability, IMDX's ROE is +2.72%, compared to OPK's ROE of -0.06%. Regarding short-term risk, IMDX is more volatile compared to OPK. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
IMDX vs CSTL Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, CSTL has a market cap of 1B. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while CSTL trades at $33.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas CSTL's P/E ratio is -50.67. In terms of profitability, IMDX's ROE is +2.72%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, IMDX is more volatile compared to CSTL. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check CSTL's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
IMDX vs FLGT Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, FLGT has a market cap of 586.5M. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while FLGT trades at $20.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas FLGT's P/E ratio is 2065.00. In terms of profitability, IMDX's ROE is +2.72%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, IMDX is more volatile compared to FLGT. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check FLGT's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
IMDX vs GRALV Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas GRALV's P/E ratio is N/A. In terms of profitability, IMDX's ROE is +2.72%, compared to GRALV's ROE of N/A. Regarding short-term risk, IMDX is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for IMDX.Check GRALV's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
IMDX vs NEO Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, NEO has a market cap of 473M. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while NEO trades at $18.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas NEO's P/E ratio is 141.62. In terms of profitability, IMDX's ROE is +2.72%, compared to NEO's ROE of -0.06%. Regarding short-term risk, IMDX is more volatile compared to NEO. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check NEO's competition here
Global Cord Blood Corporation (NYSE: CO)
IMDX vs CO Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas CO's P/E ratio is 5.06. In terms of profitability, IMDX's ROE is +2.72%, compared to CO's ROE of +0.11%. Regarding short-term risk, IMDX is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for IMDX.Check CO's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
IMDX vs MYGN Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, MYGN has a market cap of 358M. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while MYGN trades at $3.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas MYGN's P/E ratio is -29.15. In terms of profitability, IMDX's ROE is +2.72%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, IMDX is less volatile compared to MYGN. This indicates lower risk in terms of short-term price fluctuations for IMDX.Check MYGN's competition here
Prenetics Global Limited (NASDAQ: PRENW)
IMDX vs PRENW Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, PRENW has a market cap of 303.1M. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while PRENW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas PRENW's P/E ratio is N/A. In terms of profitability, IMDX's ROE is +2.72%, compared to PRENW's ROE of -0.49%. Regarding short-term risk, IMDX is less volatile compared to PRENW. This indicates lower risk in terms of short-term price fluctuations for IMDX.Check PRENW's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
IMDX vs FLDM Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas FLDM's P/E ratio is -4.74. In terms of profitability, IMDX's ROE is +2.72%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, IMDX is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for IMDX.Check FLDM's competition here
Biodesix, Inc. (NASDAQ: BDSX)
IMDX vs BDSX Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, BDSX has a market cap of 223M. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while BDSX trades at $27.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas BDSX's P/E ratio is -8.64. In terms of profitability, IMDX's ROE is +2.72%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, IMDX is more volatile compared to BDSX. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check BDSX's competition here
Exagen Inc. (NASDAQ: XGN)
IMDX vs XGN Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, XGN has a market cap of 177.6M. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while XGN trades at $7.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas XGN's P/E ratio is -9.07. In terms of profitability, IMDX's ROE is +2.72%, compared to XGN's ROE of -1.22%. Regarding short-term risk, IMDX is more volatile compared to XGN. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check XGN's competition here
Genetron Holdings Limited (NASDAQ: GTH)
IMDX vs GTH Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas GTH's P/E ratio is -1.11. In terms of profitability, IMDX's ROE is +2.72%, compared to GTH's ROE of -1.01%. Regarding short-term risk, IMDX is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
IMDX vs GENE Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas GENE's P/E ratio is -38.25. In terms of profitability, IMDX's ROE is +2.72%, compared to GENE's ROE of -1.85%. Regarding short-term risk, IMDX is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check GENE's competition here
Sera Prognostics, Inc. (NASDAQ: SERA)
IMDX vs SERA Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, SERA has a market cap of 76.4M. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while SERA trades at $2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas SERA's P/E ratio is -3.08. In terms of profitability, IMDX's ROE is +2.72%, compared to SERA's ROE of -0.47%. Regarding short-term risk, IMDX is more volatile compared to SERA. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check SERA's competition here
Precipio, Inc. (NASDAQ: PRPO)
IMDX vs PRPO Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, PRPO has a market cap of 48.6M. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while PRPO trades at $27.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas PRPO's P/E ratio is -104.73. In terms of profitability, IMDX's ROE is +2.72%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, IMDX is more volatile compared to PRPO. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check PRPO's competition here
MDxHealth S.A. (NASDAQ: MDXH)
IMDX vs MDXH Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, MDXH has a market cap of 36.3M. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while MDXH trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas MDXH's P/E ratio is -1.86. In terms of profitability, IMDX's ROE is +2.72%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, IMDX is more volatile compared to MDXH. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check MDXH's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
IMDX vs QUCY Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, QUCY has a market cap of 30.1M. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while QUCY trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas QUCY's P/E ratio is -0.06. In terms of profitability, IMDX's ROE is +2.72%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, IMDX is more volatile compared to QUCY. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check QUCY's competition here
Akumin Inc. (NASDAQ: AKU)
IMDX vs AKU Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas AKU's P/E ratio is -0.13. In terms of profitability, IMDX's ROE is +2.72%, compared to AKU's ROE of -5.32%. Regarding short-term risk, IMDX is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for IMDX.Check AKU's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
IMDX vs CEMI Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas CEMI's P/E ratio is -0.63. In terms of profitability, IMDX's ROE is +2.72%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, IMDX is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
IMDX vs ENZ Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas ENZ's P/E ratio is -2.24. In terms of profitability, IMDX's ROE is +2.72%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, IMDX is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for IMDX.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
IMDX vs PMD Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas PMD's P/E ratio is -5.24. In terms of profitability, IMDX's ROE is +2.72%, compared to PMD's ROE of -0.32%. Regarding short-term risk, IMDX is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
IMDX vs ME Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas ME's P/E ratio is -0.03. In terms of profitability, IMDX's ROE is +2.72%, compared to ME's ROE of -42.03%. Regarding short-term risk, IMDX is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
IMDX vs MYNZ Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, IMDX's ROE is +2.72%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, IMDX is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for IMDX.Check MYNZ's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
IMDX vs BNR Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, BNR has a market cap of 12.3M. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while BNR trades at $11.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas BNR's P/E ratio is -13.33. In terms of profitability, IMDX's ROE is +2.72%, compared to BNR's ROE of -0.11%. Regarding short-term risk, IMDX is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for IMDX.Check BNR's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
IMDX vs CHEK Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas CHEK's P/E ratio is -0.43. In terms of profitability, IMDX's ROE is +2.72%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, IMDX is more volatile compared to CHEK. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check CHEK's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
IMDX vs ADVB Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, ADVB has a market cap of 10.8M. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while ADVB trades at $7.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas ADVB's P/E ratio is -70.73. In terms of profitability, IMDX's ROE is +2.72%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, IMDX is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for IMDX.Check ADVB's competition here
Centogene N.V. (NASDAQ: CNTG)
IMDX vs CNTG Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas CNTG's P/E ratio is -0.23. In terms of profitability, IMDX's ROE is +2.72%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, IMDX is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check CNTG's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
IMDX vs NDRA Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, NDRA has a market cap of 7.5M. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while NDRA trades at $5.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas NDRA's P/E ratio is -0.76. In terms of profitability, IMDX's ROE is +2.72%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, IMDX is more volatile compared to NDRA. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check NDRA's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
IMDX vs APDN Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas APDN's P/E ratio is -0.10. In terms of profitability, IMDX's ROE is +2.72%, compared to APDN's ROE of -7.23%. Regarding short-term risk, IMDX is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for IMDX.Check APDN's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
IMDX vs BIAFW Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, BIAFW has a market cap of 6.4M. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while BIAFW trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas BIAFW's P/E ratio is 0.68. In terms of profitability, IMDX's ROE is +2.72%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, IMDX is less volatile compared to BIAFW. This indicates lower risk in terms of short-term price fluctuations for IMDX.Check BIAFW's competition here
Invitae Corporation (NYSE: NVTA)
IMDX vs NVTA Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas NVTA's P/E ratio is -0.00. In terms of profitability, IMDX's ROE is +2.72%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, IMDX is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for IMDX.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDX)
IMDX vs LMDX Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas LMDX's P/E ratio is -0.01. In terms of profitability, IMDX's ROE is +2.72%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, IMDX is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for IMDX.Check LMDX's competition here
LumiraDx Limited (NASDAQ: LMDXW)
IMDX vs LMDXW Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, IMDX's ROE is +2.72%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, IMDX is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for IMDX.Check LMDXW's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
IMDX vs BIAF Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, BIAF has a market cap of 3.3M. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while BIAF trades at $7.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas BIAF's P/E ratio is -0.93. In terms of profitability, IMDX's ROE is +2.72%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, IMDX is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for IMDX.Check BIAF's competition here
DermTech, Inc. (NASDAQ: DMTK)
IMDX vs DMTK Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas DMTK's P/E ratio is -0.04. In terms of profitability, IMDX's ROE is +2.72%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, IMDX is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for IMDX.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
IMDX vs NOTV Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas NOTV's P/E ratio is -0.03. In terms of profitability, IMDX's ROE is +2.72%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, IMDX is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for IMDX.Check NOTV's competition here
SeqLL Inc. (NASDAQ: SQL)
IMDX vs SQL Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas SQL's P/E ratio is -0.40. In terms of profitability, IMDX's ROE is +2.72%, compared to SQL's ROE of -30.46%. Regarding short-term risk, IMDX is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for IMDX.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
IMDX vs AWH Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas AWH's P/E ratio is -0.09. In terms of profitability, IMDX's ROE is +2.72%, compared to AWH's ROE of +1.62%. Regarding short-term risk, IMDX is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check AWH's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
IMDX vs HTGM Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas HTGM's P/E ratio is -0.03. In terms of profitability, IMDX's ROE is +2.72%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, IMDX is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
IMDX vs BIOC Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas BIOC's P/E ratio is -0.01. In terms of profitability, IMDX's ROE is +2.72%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, IMDX is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for IMDX.Check BIOC's competition here
iSpecimen Inc. (NASDAQ: ISPC)
IMDX vs ISPC Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, ISPC has a market cap of 204.1K. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while ISPC trades at $1.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas ISPC's P/E ratio is -0.05. In terms of profitability, IMDX's ROE is +2.72%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, IMDX is more volatile compared to ISPC. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check ISPC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
IMDX vs SQLLW Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, IMDX's ROE is +2.72%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, IMDX is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for IMDX.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
IMDX vs WGSWW Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, IMDX's ROE is +2.72%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, IMDX is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check WGSWW's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
IMDX vs BNGOW Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas BNGOW's P/E ratio is N/A. In terms of profitability, IMDX's ROE is +2.72%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, IMDX is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for IMDX.Check BNGOW's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
IMDX vs MEUSW Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas MEUSW's P/E ratio is N/A. In terms of profitability, IMDX's ROE is +2.72%, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, IMDX is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for IMDX.Check MEUSW's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
IMDX vs PRXL Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, PRXL has a market cap of 0. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas PRXL's P/E ratio is 42.97. In terms of profitability, IMDX's ROE is +2.72%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, IMDX is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check PRXL's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
IMDX vs NDRAW Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas NDRAW's P/E ratio is N/A. In terms of profitability, IMDX's ROE is +2.72%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, IMDX is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for IMDX.Check NDRAW's competition here
Danaher Corporation (NYSE: DHR-PA)
IMDX vs DHR-PA Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, IMDX's ROE is +2.72%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, IMDX is more volatile compared to DHR-PA. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check DHR-PA's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
IMDX vs CHEKZ Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, IMDX's ROE is +2.72%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, IMDX is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for IMDX.Check CHEKZ's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
IMDX vs OCDX Comparison September 2026
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IMDX stands at 129.8M. In comparison, OCDX has a market cap of 0. Regarding current trading prices, IMDX is priced at $4.02 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IMDX currently has a P/E ratio of -2.70, whereas OCDX's P/E ratio is -42.28. In terms of profitability, IMDX's ROE is +2.72%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, IMDX is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for IMDX.Check OCDX's competition here